Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

NCT07499271 PHASE2 RECRUITING

To evaluate the efficacy and safety of Genetic subtype-matched targeted therapy in the treatment of treatment-naive diffuse large B-cell lymphoma with TP53 mutation.

Details

Lead sponsor	The First Affiliated Hospital of Soochow University
Phase	PHASE2
Status	RECRUITING
Enrolment	35
Start date	Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

• POLA-R-CHP
• Orelabrutinib

Countries

China